Clinical trials: multiple sclerosis
Multiple Sclerosis
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week…
- Trial name
- DreaMS (NCT01226745)
- Testing
- ONO-4641
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 340 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Long-Term Effects of Torso-Weighting
The goal of this pilot study is to test the protocol for investigating the longer-term effects of torso weighting on physical activity, number of falls, and muscle activation (when muscles turn on and off and how intensely) in…
- Trial name
- TWPS (NCT02743312)
- Testing
- Torso Weights, Fitbit Flex
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- San Francisco State University
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Amyotrophic Lateral Sclerosis
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
- Trial name
- VITALITY-ALS (NCT02496767)
- Testing
- Tirasemtiv
- Where
- 81 sites in United States, Belgium and 9 more
- Volunteers
- 744 people
- Sponsor
- Cytokinetics
Multiple Sclerosis
Protective Stepping in People With MS
Falls are common in Veterans with multiple sclerosis (MS), and current rehabilitation approaches to reduce falls are inadequate.
- Trial name
- PRO-STEP (NCT03551665)
- Testing
- Protective step training
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Relapsing-Remitting
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223…
- Trial name
- NCT00930553
- Testing
- alemtuzumab
- Where
- 176 sites in United States, Argentina and 21 more
- Volunteers
- 1,314 people
- Sponsor
- Genzyme, a Sanofi Company
Detrusor Muscle Hyperactivity
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects…
- Trial name
- NCT01357980
- Testing
- Botulinum toxin type A
- Where
- 17 sites in Czechia, France and 3 more
- Volunteers
- 47 people
- Sponsor
- Ipsen
Multiple Sclerosis, Fatigue
Ketamine for Treatment of MS Fatigue
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system and, after trauma, is the most common cause of disability in young adults, affecting more than 400,000 individuals…
- Trial name
- NCT03500289
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS.
- Trial name
- NCT02688985
- Testing
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 131 people
- Sponsor
- Genentech, Inc.
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.
- Trial name
- PREFERMS (NCT01623596)
- Testing
- Fingolimod, Disease Modifying therapy
- Where
- 123 sites in United States, Puerto Rico
- Volunteers
- 881 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Memantine for Spasticity in MS Patients
Participants (n=20) will be identified at routine care visits performed at the Rochester Multiple Sclerosis Center. Eligible participants will have MS by McDonald Criteria,7 and will have a modified Ashworth spasticity rating8 of…
- Trial name
- NCT00638027
- Testing
- memantine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS I (NCT02792218)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 930 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Fatigue
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
This study assesses the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo…
- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Trial name
- DREAM (NCT03110315)
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Theodore R. Brown, MD MPH
Multiple Sclerosis
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis
The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis.
- Trial name
- NCT00997438
- Testing
- Lipoic Acid
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Portland VA Medical Center
Multiple Sclerosis, Relapsing-Remitting
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with relapsing forms of multiple sclerosis.
- Trial name
- ReBUILD (NCT02040298)
- Testing
- Clemastine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
- Trial name
- OPTIMUM (NCT02425644)
- Testing
- ponesimod, teriflunomide
- Where
- 162 sites in United States, Belarus and 26 more
- Volunteers
- 1,133 people
- Sponsor
- Actelion
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis, Neurogenic Bladder
Vaginal Estriol in Multiple Sclerosis
Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS…
- Trial name
- NCT03774407
- Testing
- vaginal estriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Texas Tech University Health Sciences Center
Relapsing-Remitting Multiple Sclerosis
Natalizumab (Tysabri) Re-Initiation of Dosing
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to…
- Trial name
- STRATA (NCT00297232)
- Testing
- Natalizumab
- Where
- 112 sites in Australia, Belgium and 19 more
- Volunteers
- 1,094 people
- Sponsor
- Biogen